Akamatsu Y, Fuchimoto S, Orita K
First Department of Surgery, Okayama University Medical School.
Jpn J Cancer Res. 1992 Jun;83(6):656-60. doi: 10.1111/j.1349-7006.1992.tb00140.x.
The aim of this study was to investigate the influence of oral administration of OK-432 on the tumor growth of tumor-bearing mice. In addition, the changing pattern of the splenic lymphocyte subsets of tumor-bearing mice was evaluated by flow cytometry. OK-432 at a dose of 0.1, 1 or 10 KE was administered orally every 3 days or every other day for 30 days to subcutaneously Meth A tumor-inoculated mice. The tumor growth was significantly inhibited in the 1 KE every 3 days group, in the 1 KE every other day group and in the 10 KE every 3 days group. In the 10 KE every other day group, OK-432 inhibited the tumor growth on days 10 and 20, while the agent did not show a marked inhibitory effect on day 30. The percentages of splenic L3T4-positive cells and splenic asialo GM1-positive cells were significantly increased in the 1 KE every other day group, while the Lyt2+/Thy1.2+ ratio was decreased. On the other hand, in the 10 KE every other day group, OK-432 showed no effect on the percentages of splenic L3T4-positive cells and Lyt2+/Thy1.2+ ratio on days 20 and 30. Our results suggest that the antitumor effect of oral administration of OK-432 may be correlated with the changing pattern of L3T4-positive cells and Lyt2+/Thy1.2+ ratio.
本研究旨在探讨口服溶链菌制剂（OK-432）对荷瘤小鼠肿瘤生长的影响。此外，通过流式细胞术评估荷瘤小鼠脾淋巴细胞亚群的变化模式。将剂量为0.1、1或10KE的OK-432每3天或每隔1天口服给药30天，用于皮下接种Meth A肿瘤的小鼠。每3天给予1KE组、每隔1天给予1KE组和每3天给予10KE组的肿瘤生长均受到显著抑制。在每隔1天给予10KE组中，OK-432在第10天和第20天抑制了肿瘤生长，而在第30天该药物未显示出明显的抑制作用。每隔1天给予1KE组的脾L3T4阳性细胞和脾去唾液酸GM1阳性细胞百分比显著增加，而Lyt2+/Thy1.2+比值降低。另一方面，在每隔1天给予10KE组中，OK-432在第20天和第30天对脾L3T4阳性细胞百分比和Lyt2+/Thy1.2+比值无影响。我们的结果表明，口服OK-432的抗肿瘤作用可能与L3T4阳性细胞和Lyt2+/Thy1.2+比值的变化模式相关。
